Low-dose rectal indomethacin to prevent post-ERCP pancreatitis: results of a large Chinese multicenter randomized noninferiority trial
Endoscopy · 01.07.2026 · 58 (07) · 689-698
DOI: 10.1055/a-2840-3508 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Endoscopy, erschienen am 01.07.2026. Verfasst von Zhi-Peng Qi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Hospital Fudan University, Endoscopy Center, China, Shanghai. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Cholangiopancreatography, Endoscopic Retrograde, Indomethacin, Pancreatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: The Shanghai Municipal Commission of Science and Technology, The National Natural Science Foundation of China, The 2022 Shanghai Eastern Talent Plan Leading Project.
Abstract (Originalsprache)
Routine rectal administration of indomethacin before endoscopic retrograde cholangiopancreatography (ERCP) is recommended for prevention of post-ERCP pancreatitis (PEP). Preliminary evidence suggests that the use of 100 mg of indomethacin can reduce the PEP rate; however, the efficacy of a lower dose for PEP prevention remains uncertain. In this randomized, single-blind, noninferiority trial conducted at four centers in China, patients (aged ≥18 years) who were scheduled to undergo ERCP and had a serum amylase level within the normal range were randomly assigned (1:1) to receive 50 mg or 100 mg rectal indomethacin before ERCP. The primary outcome was the PEP rate. Between September 11 2021 and July 1 2024, 2770 patients were enrolled, with 2562 included for intention-to-treat analysis. PEP occurred in 100 (7.7%) of the 1293 patients in the regular-dose group and 103 (8.1%) of the 1269 patients in the low-dose group (risk difference 0.38%; 95%CI –1.71 to 2.47; P = 0.72 for noninferiority). For prevention of PEP, 50 mg of indomethacin was noninferior to 100 mg. The prophylactic use of 50 mg of indomethacin can therefore be considered for PEP prevention in the Chinese population. In addition, for people who have a history of pancreatitis, 100 mg of rectal indomethacin may be preferable for prevention of PEP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zhongshan Hospital Fudan University, Endoscopy Center, China, Shanghai.
- Fudan University, Endoscopy Research Institute, China, Shanghai.
- Shanghai Collaborative Innovation Center of Endoscopy, China, Shanghai.
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Department of Gastroenterology, China, Shanghai.
- Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Department of Gastroenterology, China, Shanghai.
- Xuhui Hospital, Zhongshan Hospital of Fudan University, Endoscopy Center, China, Shanghai.
ORCID-Profile: Ming-Yan Cai, Ping-Hong Zhou
Förderung
- The Shanghai Municipal Commission of Science and Technology
- The National Natural Science Foundation of China
- The 2022 Shanghai Eastern Talent Plan Leading Project
Zitieren
APA
Qi, Z. P., Wan, R., Wan, X. J., Chen, Z. H., Cai, M. Y., He, D. L., Cai, S. L., Li, B., Li, Q. L., Lin, S. L., Zhou, P. H., Zhong, Y. S., & Study Group* (2026). Low-dose rectal indomethacin to prevent post-ERCP pancreatitis: results of a large Chinese multicenter randomized noninferiority trial. Endoscopy, 58(07), 689-698. https://doi.org/10.1055/a-2840-3508
Vancouver
Qi ZP, Wan R, Wan XJ, Chen ZH, Cai MY, He DL, et al. Low-dose rectal indomethacin to prevent post-ERCP pancreatitis: results of a large Chinese multicenter randomized noninferiority trial. Endoscopy. 2026;58(07):689-698. doi:10.1055/a-2840-3508
BibTeX
@article{Qi2026,
author = {Qi, Zhi-Peng and Wan, Rong and Wan, Xin-Jian and Chen, Zhang-Han and Cai, Ming-Yan and He, Dong-Li and Cai, Shi-Lun and Li, Bing and Li, Quan-Lin and Lin, Sheng-Li and Zhou, Ping-Hong and Zhong, Yun-Shi and Study Group*, Study Group*},
title = {Low-dose rectal indomethacin to prevent post-ERCP pancreatitis: results of a large Chinese multicenter randomized noninferiority trial},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {07},
pages = {689--698},
doi = {10.1055/a-2840-3508}
}
EUVIMED